Charlotte Thålin

Dr. Charlotte Thålin


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2019 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
CTCharlotte Thålin
Charlotte Thålin
YHYohei Hisada
Yohei Hisada
SLStaffan Lundström
Staffan Lundström
NMNigel Mackman
Nigel Mackman
HWHåkan Wallén
Håkan Wallén
Recent studies have demonstrated a role of neutrophils in both venous and arterial thrombosis. A key prothrombotic feature of neutrophils is their ability to release web-like structures composed of DNA filaments coated with histones and granule proteins referred to as neutrophil extracellular traps (NETs). NETs were discovered over a decade ago as part of our first line of host defense against invading microorganisms. Although NETs have a protective role against pathogens, recent data suggest that an uncontrolled and excessive NET formation within the vasculature may contribute to pathological thrombotic disorders. In vitro studies suggest that NETs promote vessel occlusion by providing a scaffold for platelets, red blood cells, extracellular vesicles, and procoagulant molecules, such as von Willebrand factor and tissue factor. In addition, NET components enhance coagulation by both activating the intrinsic pathway and degrading an inhibitor of the extrinsic pathway (tissue factor pathway inhibitor). NET formation has, therefore, been proposed to contribute to thrombus formation and propagation in arterial, venous, and cancer-associated thrombosis. This review will describe animal and human studies suggesting a role of NETs in the pathogenesis of various thrombotic disorders. Targeting NETs may be a novel approach to reduce thrombosis without affecting hemostasis.

18 May 2021 in JAMA
Verified
Journal Article
Open access
PDF file
SHSebastian Havervall
Sebastian Havervall
ARAxel Rosell
Axel Rosell
MPMia Phillipson
Mia Phillipson
SMSara M. Mangsbo
Sara M. Mangsbo
PNPeter Nilsson
Peter Nilsson
CTCharlotte Thålin
Charlotte Thålin
Approximately 80% of hospitalized patients with COVID-19 report persistent symptoms several months after infection onset.1,2 However, knowledge of long-term outcomes among individuals with mild COVID-19 is scarce, and prevalence data are hampered by selection bias and suboptimal control groups.3,4 This cohort study investigated COVID-19–related long-term symptoms in health care professionals.

8 October 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
ARAnn-Sofie Rudberg
Ann-Sofie Rudberg
SHSebastian Havervall
Sebastian Havervall
AMAnna Månberg
Anna Månberg
AFAugust Jernbom Falk
August Jernbom Falk
KAKatherina Aguilera
Katherina Aguilera
CTCharlotte Thålin
Charlotte Thålin
SARS-CoV-2 may pose an occupational health risk to healthcare workers. Here, we report the seroprevalence of SARS-CoV-2 antibodies, self-reported symptoms and occupational exposure to SARS-CoV-2 among healthcare workers at a large acute care hospital in Sweden. The seroprevalence of IgG antibodies against SARS-CoV-2 was 19.1% among the 2149 healthcare workers recruited between April 14th and May 8th 2020, which was higher than the reported regional seroprevalence during the same time period. Symptoms associated with seroprevalence were anosmia (odds ratio (OR) 28.4, 95% CI 20.6–39.5) and ageusia (OR 19.2, 95% CI 14.3–26.1). Seroprevalence was also associated with patient contact (OR 2.9, 95% CI 1.9–4.5) and covid-19 patient contact (OR 3.3, 95% CI 2.2–5.3). These findings imply an occupational risk for SARS-CoV-2 infection among healthcare workers. Continued measures are warranted to assure healthcare workers safety and reduce transmission from healthcare workers to patients and to the community.

14 September 2022 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
SHSebastian Havervall
Sebastian Havervall
UMUlrika Marking
Ulrika Marking
JSJulia Svensson
Julia Svensson
NGNina Greilert-Norin
Nina Greilert-Norin
PBPhilip Bacchus
Philip Bacchus
CTCharlotte Thålin
Charlotte Thålin
Mucosal IgA can provide immunity against respiratory viruses.1 Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) boosts mucosal IgA responses,2 and neutralizing IgA, including neutralizing IgA against the B.1.1.529 (omicron) variant of SARS-CoV-2, has been detected after infection with wild-type SARS-CoV-2.3 However, the potential role of mucosal IgA in protection against SARS-CoV-2 infection is still largely unknown.

11 January 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CTCharlotte Thålin
Charlotte Thålin
SLStaffan Lundström
Staffan Lundström
CSCedric Seignez
Cedric Seignez
MDMaud Daleskog
Maud Daleskog
ALAnnika Lundström
Annika Lundström
MDMélanie Demers
Mélanie Demers
Citrullinated histone H3 (H3Cit) is a central player in the neutrophil release of nuclear chromatin, known as neutrophil extracellular traps (NETs). NETs have been shown to elicit harmful effects on the host, and were recently proposed to promote tumor progression and spread. Here we report significant elevations of plasma H3Cit in patients with advanced cancer compared with age-matched healthy individuals. These elevations were specific to cancer patients as no increase was observed in severely ill and hospitalized patients with a higher non-malignant comorbidity. The analysis of neutrophils from cancer patients showed a higher proportion of neutrophils positive for intracellular H3Cit compared to severely ill patients. Moreover, the presence of plasma H3Cit in cancer patients strongly correlated with neutrophil activation markers neutrophil elastase (NE) and myeloperoxidase (MPO), and the inflammatory cytokines interleukin-6 and -8, known to induce NETosis. In addition, we show that high levels of circulating H3Cit strongly predicted poor clinical outcome in our cohort of cancer patients with a 2-fold increased risk for short-term mortality. Our results also corroborate the association of NE, interleukin-6 and -8 with poor clinical outcome. Taken together, our results are the first to unveil H3Cit as a potential diagnostic and prognostic blood marker associated with an exacerbated inflammatory response in patients with advanced cancer.

1 February 2021 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
PDF file
ARAxel Rosell
Axel Rosell
SHSebastian Havervall
Sebastian Havervall
FMFien von Meijenfeldt
Fien von Meijenfeldt
YHYohei Hisada
Yohei Hisada
KAKatherina Aguilera
Katherina Aguilera
CTCharlotte Thålin
Charlotte Thålin
Objective: Patients with coronavirus disease 2019 (COVID-19) have a high rate of thrombosis. We hypothesized that severe acute respiratory syndrome coronavirus 2 infection leads to induction of TF (tissue factor) expression and increased levels of circulating TF-positive extracellular vesicles (EV) that may drive thrombosis. Approach and Results: We measured levels of plasma EV TF activity in 100 patients with COVID-19 with moderate and severe disease and 28 healthy controls. Levels of EV TF activity were significantly higher in patients with COVID-19 compared with controls. In addition, levels of EV TF activity were associated with disease severity and mortality. Finally, levels of EV TF activity correlated with several plasma markers, including D-dimer, which has been shown to be associated with thrombosis in patients with COVID-19. Conclusions: Our results indicate that severe acute respiratory syndrome coronavirus 2 infection induces the release of TF-positive EVs into the circulation that are likely to contribute to thrombosis in patients with COVID-19. EV TF activity was also associated with severity and mortality.